Clinical Context
Sleep disturbances and type 2 diabetes share a bidirectional relationship that is often underappreciated in clinical practice. Approximately 50-80% of patients with type 2 diabetes report sleep problems, with insomnia being particularly prevalent. Poor sleep impairs glucose metabolism through multiple mechanisms: reduced insulin sensitivity, increased cortisol and sympathetic activation, altered appetite hormones (increased ghrelin, decreased leptin), and decreased physical activity due to fatigue.
Conversely, hyperglycemia disrupts sleep through nocturia, restless legs syndrome, peripheral neuropathy, and obstructive sleep apnea (common in patients with diabetes and obesity). This creates a vicious cycle where poor sleep worsens diabetes control, which in turn worsens sleep quality.
Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia according to major guidelines, outperforming sleep medications for long-term outcomes without risks of dependence or side effects. This trial tests whether treating insomnia with CBT-I can simultaneously improve sleep and glucose metabolism.
Study Summary (PICO Framework)
Summary: In adults with type 2 diabetes and comorbid insomnia, eight weeks of remotely delivered cognitive behavioral therapy for insomnia (CBT-I) significantly improved sleep regularity, reduced anxiety, and lowered fasting glucose by 34 mg/dL compared to online health education, with no adverse effects and high participant satisfaction.
| PICO | Description |
|---|---|
| Population | Adults with non-insulin-treated type 2 diabetes and clinically diagnosed insomnia. |
| Intervention | Eight weekly 1-hour online sessions of CBT-I (sleep restriction, stimulus control, cognitive restructuring, sleep hygiene). |
| Comparison | Eight weekly 1-hour online health education sessions. |
| Outcome | Improved sleep regularity (-22 min variability, p=0.031), reduced anxiety (p=0.039), fasting glucose reduction of 34 mg/dL in per-protocol analysis (p=0.001). |
Clinical Pearls
1. The 34 mg/dL fasting glucose reduction rivals pharmacotherapy. This magnitude of fasting glucose improvement is comparable to adding a second-line diabetes medication. Achieving this through a behavioral sleep intervention highlights the profound metabolic impact of treating insomnia.
2. Sleep regularity may matter as much as sleep duration. The study found improvements in sleep regularity (reduced variability in sleep timing) rather than just total sleep time. Encouraging consistent bed and wake times may be as important as recommending 7-8 hours of sleep.
3. Remote delivery makes CBT-I accessible. Traditional in-person CBT-I requires trained therapists and multiple visits, limiting access. This study demonstrates that online group sessions are effective, potentially expanding reach to patients who cannot access specialty sleep medicine.
4. Anxiety reduction is an added benefit. Sleep disturbance and anxiety are closely linked, and both affect diabetes self-management. By improving anxiety symptoms, CBT-I may have downstream benefits for dietary adherence and medication taking.
Practical Application
Screening for insomnia in diabetes care: Ask patients with diabetes about sleep quality using simple screening questions or validated instruments like the Insomnia Severity Index (ISI). Common symptoms include difficulty falling asleep, waking during the night, and non-restorative sleep.
Referring for CBT-I: For patients with chronic insomnia (symptoms ≥3 nights/week for ≥3 months), refer to a behavioral sleep medicine specialist. If in-person services are unavailable, recommend evidence-based digital programs like Somryst or Sleepio.
Key CBT-I components patients can start immediately: Sleep restriction, stimulus control (using bed only for sleep), maintaining consistent wake time, avoiding naps, reducing caffeine and alcohol.
Broader Evidence Context
This study adds to growing evidence linking sleep interventions to metabolic outcomes. Previous research has shown that sleep extension improves insulin sensitivity and that treating obstructive sleep apnea can modestly improve glucose control. The ADA Standards of Care acknowledge the importance of sleep in diabetes management.
Study Limitations
The fasting glucose improvement was seen in per-protocol analysis (those who completed the intervention), not intention-to-treat, suggesting possible selection bias. Sample size was modest. HbA1c was not reported; fasting glucose alone provides an incomplete glycemic picture. Long-term durability not assessed.
Bottom Line
Remote cognitive behavioral therapy for insomnia improves sleep regularity, reduces anxiety, and lowers fasting glucose by 34 mg/dL in adults with type 2 diabetes and insomnia. Clinicians managing diabetes should routinely screen for sleep disturbances and consider referral for CBT-I as part of comprehensive diabetes care.
Source: Kirisri S, et al. “Effects of remotely-delivered cognitive behavioral therapy for insomnia in type 2 diabetes: a randomized controlled trial.” Read article.
